Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Diovan Gets Pediatric Hypertension Nod

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis’ top seller will compete with Merck’s Cozaar in the growing pediatric high blood pressure market.

You may also be interested in...



Novartis’ Exforge To Launch By End Of June

Launch timeframe for the combination of firm’s Diovan and Pfizer’s Norvasc is a few months earlier than previously expected due to recent invalidation of Norvasc patent.

Diovan Clears FDA For Post-Myocardial Infarction Mortality Reduction

Agency also removes restriction in labeling limiting heart failure indication to patients intolerant of ACE inhibitors.

Arena Cannabinoid Pain Compound Misses In Phase IIb IBS Trial

Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel